Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The other randomization - methods for labeling drug kits.

Daniel A Coleman1, Ron Yu2

  • 1Nonclinical Biostatistics, Genentech, Inc., United States.

Contemporary Clinical Trials
|May 24, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blinding properties of methods for supplying drug kits to investigational sites.

Contemporary clinical trials communications·2018
Same author

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.

International journal of cancer·2016
Same author

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2016
Same author

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

The Lancet. Oncology·2014
Same author

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology·2014
Same author

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Investigational new drugs·2014
Same journal

The sequential cohort randomized clinical trial: A study design for community-engaged clinical research in a rural American Indian community.

Contemporary clinical trials·2026
Same journal

Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression.

Contemporary clinical trials·2026
Same journal

Effectiveness of clinical trial recruitment strategies in a safety-net hospital.

Contemporary clinical trials·2026
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
See all related articles

Scrambled kit lists offer the most flexibility for clinical trials, avoiding operational deficiencies of blocked lists. These lists enhance blinding and simplify management in large pharmaceutical studies.

Area of Science:

  • Clinical trial operations
  • Pharmaceutical drug development
  • Randomized controlled trials

Background:

  • Blinded randomized clinical trials commonly use drug kits to maintain patient and investigator blinding.
  • Kit lists assign unique kit IDs to drug types, ensuring proper drug administration and trial integrity.
  • Algorithms incorporating randomness are crucial for generating kit lists and randomizing patients, preserving the blind.

Purpose of the Study:

  • To review the operational characteristics of three types of kit lists: blocked, double randomized, and scrambled.
  • To discuss the operational benefits pharmaceutical companies can achieve using scrambled kit lists.
  • To provide an overview of challenges in generating and extending kit lists for large trials.

Main Methods:

Keywords:
Blocked kit listDouble randomized kit listDrug kitScrambled kit list

Related Experiment Videos

  • Review of operational characteristics of blocked, double randomized, and scrambled kit lists.
  • Comparative analysis of the advantages and disadvantages of each kit list type.
  • Evaluation of flexibility and extensibility for large-scale clinical trials.

    • Main Results:

    • Blocked kit lists have known unblinding and operational deficiencies.
    • Double randomized and scrambled kit lists avoid the difficulties associated with blocked lists.
    • Scrambled kit lists offer superior ease of extension compared to double randomized lists due to randomly sized gaps.

    Conclusions:

    • Scrambled kit lists provide the greatest flexibility among the reviewed types.
    • The adoption of scrambled kit lists has yielded significant operational benefits in practice.
    • Scrambled kit lists are recommended for enhancing efficiency and integrity in clinical trial drug packaging.